FDA updates on BPA activities
This article was originally published in The Tan Sheet
Executive Summary
Infant formula manufacturers are testing product samples on an ongoing basis to minimize bisphenol A in food contact applications and identify safe levels of the chemical. The Center for Food Safety and Applied Nutrition is analyzing several infant formula brands with an updated testing method, Mitchell Cheeseman, deputy director of the Office of Food Additive Safety, said at an FDA Science Board meeting Feb. 24 in Gaithersburg, Md. Recent testing of 57 samples found a range of 0.02 to 10.55 µg of BPA per kg of infant formula, which Cheeseman calls "comparable to the existing data" on formula products. He added that FDA encourages industry to follow a voluntary "code of practice" - essentially good manufacturing practices for producing and filling infant formula cans - "to minimize BPA migration from existing packaging materials into" the product. The presentation was part of an ongoing dialog about BPA's safety in food contact applications (1"The Tan Sheet" Feb. 16, 2009, In Brief)
You may also be interested in...
Science Board to convene in August
FDA's scientific advisory panel will meet Aug. 17 in Rockville, Md., to discuss plans for an "additional subcommittee for the review of research" at the Center for Food Safety and Applied Nutrition, as well as receive updates on the agency's assessment of bisphenol A (1"The Tan Sheet" March 2, 2009, In Brief)
FDA responds to Science Board’s BPA review
The agency is formulating a response to its Science Board's review of FDA's draft assessment of bisphenol A's safety in food contact applications. Associate Commissioner for Science Norris Alderson initially replied to the board in a December 2008 letter, agreeing that FDA should focus on BPA applications that might impact infants, including formula packaging (1"The Tan Sheet" Jan. 5, 2009, In Brief). According to a Feb. 9 release, FDA and Health Canada officials held a forum Jan. 30 with manufacturers from both countries to discuss ongoing BPA reduction efforts. FDA says an international regulatory consensus holds that BPA exposure through food packages does not pose a risk to the general population, but the agency continues to review research on the potential low-dose effects of BPA
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.